As the U.S. prepares for a fresh round of tariffs under the policies of former President Donald Trump, pharmaceutical and skincare behemoths such as Novo Nordisk A/S and Galderma, producers of Ozempic, Wegovy, and Cetaphil, are in the firing line. The effect of these tariffs on international trade has caused alarm regarding supply chain disruption and possible price increases for vital medicines and skincare products.
Novo Nordisk, one of the leading players in the obesity and diabetes medication sector, admits it is not “immune” to the economic implications of these tariffs. With Wegovy and Ozempic so popular globally, any trade constraints would impact manufacturing costs and accessibility, which in turn could make prices higher for consumers and cause further pressure for healthcare providers.
Likewise, Galderma, a company producing Cetaphil and other dermatology solutions, is gearing up for potential hardship in the procurement of raw materials and keeping prices competitive. These tariffs are expected by industry experts to prompt cost-cutting, impacting research, innovation, and the availability of reliable medical and skincare offerings.
While pharmaceutical and consumer health companies ride out these uncertainties, stakeholders are watching policy developments closely and weighing strategic adjustments to counteract risks. The potential economic ripple impact of these tariffs goes beyond corporate earnings, affecting healthcare access and affordability for millions of patients who depend on these essential products.
